Ailevi akdeniz ateşi (AAA), (familialmediterranean fever; FMF) tanılı hastalarda çözünür ürokinaz plazminojen aktivatör reseptör (SuPAR) düzeylerinin proteinüri ile ilişkisi
Yükleniyor...
Dosyalar
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Selçuk Üniversitesi, Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
AMAÇ: Bu çalışmada, Ailesel Akdeniz Ateşi (AAA) tanılı hastalarda serum Çözünür Ürokinaz Plazminojen Aktivatör Reseptör (SuPAR) konsantrasyon artışının proteinüri ile ilişkisi araştırılmıştır. METOT: Bu çalışmamızda Selçuk Üniversitesi Tıp Fakültesi Hastanesi'nde 18 yaş ve üzeri AAA hastalığı nedeniyle takip edilen hastalar analiz edilmiştir. Çalışmamızda 110 AAA tanılı hasta ve 40 sağlıklı gönüllülerden alınan kan örnekleri incelenmiştir. BULGULAR: 110 olgudan oluşan AAA olgularının %45,5'i, kontrol grubunun ise % 62,5'i erkekti. AAA olgularının yaş ortalaması 34,2, kontrol grubunun ise 32,7 idi. Poliklinik başvurusunda hastaların büyük bir kısmının aktif şikayeti yoktu (91 hasta-%82,7). Aktif şikayeti olup polikliniğe başvuran hastaların en sık başvuru nedeni % 84,2 ile karın ağrısı idi. AAA olgularının aldıkları tedaviler incelendiğinde olguların tamamının kolşisin kullandığı görüldü. Çalışmaya dahil edilen AAA hastalarının serum SuPAR düzeyi, kontrol grubuna göre istatistiksel olarak anlamlı düzeyde yüksek bulundu (p= 0,032). 500 mg üstünde proteinürisi olan hastaların median SuPAR düzeyi 289,9 ng/L bulunurken, 500 mg altı proteinürisi olan hastalarda bu düzey 438,6 ng/L idi. 500 mg üstü proteinürisi olan hastaların SuPAR düzeyi, 500 mg altı proteinürisi olan hastalara göre istatistiksel olarak anlamlı şekilde düşüktü (p=0,013). AAA tanılı olgularda tedavide IL-1 inhibitörü alan hastalar ile IL-1 inhibitörü almayan hastalar karşılaştırıldığında IL-1 inhibitörü alan 5 hastanın SuPAR düzeyleri anlamlı olarak düşük bulunmuştur (p=0,011). Bu hastaların proteinüri düzeyi anlamlı olarak yüksek (p=0,016) ve bununla ilişkili olarak kan albumin seviyeleri anlamlı olarak düşük bulunmuştur (p=0,001). SONUÇ: AAA olgularında serum SuPAR düzeyinin yüksek olduğu belirlendi. İmmün ve inflamatuar olaylarda aktivasyon belirteci olarak kabul edilen, proteinüriye neden olabilen SuPAR molekülü üzerinde yapılacak çalışmalar ile böbrek hastalıkları fizyopatolojisine ışık tutulabilir ve AAA tedavisine katkı sunulabilir.
AIM: In this study, the relationship between serum Soluble Urokinase Plasminogen Activator Receptor (SuPAR) concentration increase and proteinuria in patients diagnosed with Familial Mediterranean Fever (FMF) was investigated. METHOD: In this study, patients aged 18 years and older who were followed up in Selcuk University Medical Faculty Hospital due to FMF were analyzed. In our study, blood samples taken from 110 patients with FMF and 40 healthy volunteers were examined. RESULTS: Consisting of 110 cases, 45.5% of the FMF cases and 62.5% of the control group were male. The average age of the FMF cases was 34.2 and the control group was 32.7. Most of the patients did not have any active complaints when they applied to the outpatient clinic (91 patients - 82.7 %). The most common reason for patients presenting to the outpatient clinic with active complaints was abdominal pain with 84.2 %. When the treatments received by FMF cases were examined, it was seen that all of the cases used colchicine. Serum SuPAR levels of FMF patients included in the study were found to be statistically significantly higher than the control group (p= 0,032). While the median SuPAR level of patients with proteinuria above 500 mg was 289.9 ng/L, this level was 438.6 ng/L in patients with proteinuria below 500 mg. SuPAR levels of patients with proteinuria above 500 mg were statistically significantly lower than patients with proteinuria below 500 mg (p=0.013). When patients diagnosed with FMF were compared with patients who received IL-1 inhibitors and those who did not receive IL-1 inhibitors, SuPAR levels of 5 patients who received IL-1 inhibitors were found to be significantly lower (p = 0.011). The proteinuria level of these patients was found to be significantly higher (p=0.016) and the blood albumin levels were significantly lower (p=0.001). CONCLUSION: Serum SuPAR levels were determined to be high in FMF cases. Studies on the SuPAR molecule, which is considered an activation marker in immune and inflammatory events and can cause proteinuria, can shed light on the pathophysiology of kidney diseases and contribute to the treatment of FMF.
AIM: In this study, the relationship between serum Soluble Urokinase Plasminogen Activator Receptor (SuPAR) concentration increase and proteinuria in patients diagnosed with Familial Mediterranean Fever (FMF) was investigated. METHOD: In this study, patients aged 18 years and older who were followed up in Selcuk University Medical Faculty Hospital due to FMF were analyzed. In our study, blood samples taken from 110 patients with FMF and 40 healthy volunteers were examined. RESULTS: Consisting of 110 cases, 45.5% of the FMF cases and 62.5% of the control group were male. The average age of the FMF cases was 34.2 and the control group was 32.7. Most of the patients did not have any active complaints when they applied to the outpatient clinic (91 patients - 82.7 %). The most common reason for patients presenting to the outpatient clinic with active complaints was abdominal pain with 84.2 %. When the treatments received by FMF cases were examined, it was seen that all of the cases used colchicine. Serum SuPAR levels of FMF patients included in the study were found to be statistically significantly higher than the control group (p= 0,032). While the median SuPAR level of patients with proteinuria above 500 mg was 289.9 ng/L, this level was 438.6 ng/L in patients with proteinuria below 500 mg. SuPAR levels of patients with proteinuria above 500 mg were statistically significantly lower than patients with proteinuria below 500 mg (p=0.013). When patients diagnosed with FMF were compared with patients who received IL-1 inhibitors and those who did not receive IL-1 inhibitors, SuPAR levels of 5 patients who received IL-1 inhibitors were found to be significantly lower (p = 0.011). The proteinuria level of these patients was found to be significantly higher (p=0.016) and the blood albumin levels were significantly lower (p=0.001). CONCLUSION: Serum SuPAR levels were determined to be high in FMF cases. Studies on the SuPAR molecule, which is considered an activation marker in immune and inflammatory events and can cause proteinuria, can shed light on the pathophysiology of kidney diseases and contribute to the treatment of FMF.
Açıklama
Anahtar Kelimeler
Ailesel Akdeniz Ateşi, Çözünür Ürokinaz Plazminojen Aktivatör Reseptör, Proteinüri, Familial Mediterranean Fever, Soluble Urokinase Plasminogen Activator Receptor, Proteinüria
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Çırakoğlu, E. (2023). Ailevi akdeniz ateşi (AAA), (famılialmediterranean fever; FMF) tanılı hastalarda çözünür ürokinaz plazminojen aktivatör reseptör (SuPAR) düzeylerinin proteinüri ile ilişkisi. (Uzmanlık Tezi). Selçuk Üniversitesi, Tıp Fakültesi, Konya.
